{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:50:37Z","timestamp":1792716637206,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP22\/00158"],"award-info":[{"award-number":["PMP22\/00158"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP22\/00158"],"award-info":[{"award-number":["PMP22\/00158"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP22\/00158"],"award-info":[{"award-number":["PMP22\/00158"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM21\/00178"],"award-info":[{"award-number":["CM21\/00178"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11916-023-01183-6","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T12:02:48Z","timestamp":1698148968000},"page":"1265-1272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data"],"prefix":"10.1007","volume":"28","author":[{"given":"Carmen","family":"S\u00e1nchez-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0038-3406","authenticated-orcid":false,"given":"Ana Beatriz","family":"Gago-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-1064","authenticated-orcid":false,"given":"David","family":"Garc\u00eda-Azor\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-6002","authenticated-orcid":false,"given":"\u00c1ngel Luis","family":"Guerrero-Peral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-1503","authenticated-orcid":false,"given":"Alicia","family":"Gonzalez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"issue":"19","key":"1183_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M \u00a0Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383(19):1866\u201376.","journal-title":"N Engl J Med"},{"issue":"1","key":"1183_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-023-01619-9","volume":"24","author":"L Fan","year":"2023","unstructured":"Fan L, Wu Y, Wei J, Xia F, Cai Y, Zhang S, et al. Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain. 2023;24(1):79.","journal-title":"J Headache Pain"},{"key":"1183_CR3","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"3","key":"1183_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","volume":"27","author":"L Stovner","year":"2007","unstructured":"Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193\u2013210.","journal-title":"Cephalalgia"},{"issue":"5","key":"1183_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11916-022-01034-w","volume":"26","author":"CK Tsai","year":"2022","unstructured":"Tsai CK, Tsai CL, Lin GY, Yang FC, Wang SJ. Sex differences in chronic migraine: focusing on clinical features, pathophysiology, and treatments. Curr Pain Headache Rep. 2022;26(5):347\u201355.","journal-title":"Curr Pain Headache Rep"},{"issue":"6","key":"1183_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"issue":"1","key":"1183_CR7","first-page":"22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22\u201333.","journal-title":"J Manag Care Pharm"},{"issue":"6","key":"1183_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334.","journal-title":"Lancet Neurol"},{"issue":"24","key":"1183_CR9","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211\u201321.","journal-title":"Neurology"},{"issue":"22","key":"1183_CR10","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322.","journal-title":"N Engl J Med"},{"issue":"10","key":"1183_CR11","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferr\u00fas","year":"2021","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol. 2021;268(10):3789\u201398.","journal-title":"J Neurol"},{"key":"1183_CR12","doi-asserted-by":"crossref","unstructured":"\u2022 Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, et\u00a0al. Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;61(2):363\u201372. Predictors in migraine.","DOI":"10.1111\/head.14032"},{"key":"1183_CR13","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, et\u00a0al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22(1):35. Predictors in migraine and CM.","DOI":"10.1186\/s10194-021-01247-1"},{"issue":"6","key":"1183_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2217\/pmt-2021-0015","volume":"11","author":"M Ashina","year":"2021","unstructured":"Ashina M, Amin FM, Kokturk P, Cohen JM, Konings M, Tassorelli C, et al. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. Pain Manag. 2021;11(6):647\u201354.","journal-title":"Pain Manag"},{"issue":"10","key":"1183_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11916-022-01077-z","volume":"26","author":"AM Murray","year":"2022","unstructured":"Murray AM, Stern JI, Robertson CE, Chiang CC. Real-world patient experience of CGRP-targeting therapy for migraine: a narrative review. Curr Pain Headache Rep. 2022;26(10):783\u201394.","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"1183_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002946","volume":"30","author":"MDP Brice\u00f1o-Casado","year":"2023","unstructured":"Brice\u00f1o-Casado MDP, Gil-Sierra MD, De-La-Calle-Riaguas B. Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series. Eur J Hosp Pharm. 2023;30(4):e19.","journal-title":"Eur J Hosp Pharm"},{"key":"1183_CR17","doi-asserted-by":"publisher","first-page":"1154420","DOI":"10.3389\/fneur.2023.1154420","volume":"14","author":"LH Overeem","year":"2023","unstructured":"Overeem LH, Lange KS, Fitzek MP, Siebert A, Steinicke M, Triller P, et al. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study. Front Neurol. 2023;14:1154420.","journal-title":"Front Neurol"},{"key":"1183_CR18","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Iannone LF, Burgalassi A, Vigani G, Tabasso G, De Cesaris F, Chiarugi A, et\u00a0al. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalalgia 2023;43(4):03331024231160519. Predictors in CM.","DOI":"10.1177\/03331024231160519"},{"issue":"5","key":"1183_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11916-019-0768-y","volume":"23","author":"I Urits","year":"2019","unstructured":"Urits I, Jones MR, Gress K, Charipova K, Fiocchi J, Kaye AD, et al. CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Curr Pain Headache Rep. 2019;23(5):29.","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"1183_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","volume":"24","author":"AS Wattiez","year":"2020","unstructured":"Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020;24(2):91\u2013100.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"1183_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23(1):67.","journal-title":"J Headache Pain"},{"issue":"7","key":"1183_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11916-022-01056-4","volume":"26","author":"YF Wang","year":"2022","unstructured":"Wang YF, Wang SJ. CGRP Targeting therapy for chronic migraine\u2014evidence from clinical trials and real-world studies. Curr Pain Headache Rep. 2022;26(7):543\u201354.","journal-title":"Curr Pain Headache Rep"},{"key":"1183_CR23","unstructured":"Informe de Posicionamiento Terap\u00e9utico de erenumab (Aimovig\u00ae) en la profilaxis de migra\u00f1a. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-erenumab-Aimovig.pdf."},{"key":"1183_CR24","unstructured":"Informe de Posicionamiento Terap\u00e9utico de galcanezumab (Emgality\u00ae) en la profilaxis de migra\u00f1a.\u00a0https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-galcanezumab-Emgality.pdf."},{"key":"1183_CR25","unstructured":"Informe de posicionamiento terap\u00e9utico de fremanezumab (Ajovy\u00ae) en la profilaxis de la migra\u00f1a. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT_11-2020-fremanezumab-Ajovy.pdf."},{"key":"1183_CR26","unstructured":"Informe de Posicionamiento Terap\u00e9utico de eptinezumab (Viepty\u00ae) en la profilaxis de migra\u00f1a. IPT-126-Vyepti-eptinezumab.pdf - svadcf.es"},{"issue":"1","key":"1183_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.","journal-title":"J Headache Pain"},{"key":"1183_CR28","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, et\u00a0al. Long-term (48\u00a0weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache. 2021;61(9):1351\u201363. Predictors in CM.","DOI":"10.1111\/head.14194"},{"key":"1183_CR29","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs. 2022;36(2):191\u2013202. Predictors in CM.","DOI":"10.1007\/s40263-021-00893-y"},{"key":"1183_CR30","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Lee HC, Cho S, Kim BK. Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study. Neurol Sci. 2023;44(7):2455\u201363. Predictors in CM.","DOI":"10.1007\/s10072-023-06683-2"},{"key":"1183_CR31","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Lowe M, Murray L, Tyagi A, Gorrie G, Miller S, Dani K. Efficacy of erenumab and factors predicting response after 3\u00a0months in treatment resistant chronic migraine: a clinical service evaluation. J Headache Pain. 2022;23(1):86. Predictors in CM.","DOI":"10.1186\/s10194-022-01456-2"},{"key":"1183_CR32","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, et\u00a0al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci. 2022;43(2):1273\u201380. Predictors in CM.","DOI":"10.1007\/s10072-021-05426-5"},{"key":"1183_CR33","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Barbanti P, Egeo G, Aurilia C, Altamura C, d\u2019Onofrio F, Finocchi C, et\u00a0al. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;23(1):138. Predictors in CM.","DOI":"10.1186\/s10194-022-01498-6"},{"issue":"11","key":"1183_CR34","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1097\/j.pain.0000000000002614","volume":"163","author":"KP Peng","year":"2022","unstructured":"Peng KP, Basedau H, Oppermann T, May A. Trigeminal sensory modulatory effects of galcanezumab and clinical response prediction. Pain. 2022;163(11):2194\u20139.","journal-title":"Pain"},{"issue":"8","key":"1183_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2260","volume":"11","author":"C Baraldi","year":"2021","unstructured":"\u2022 Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S. Predictors of response to erenumab after 12 months of treatment. Brain Behav. 2021;11(8):e2260. Predictors in migraine.","journal-title":"Brain and Behavior"},{"key":"1183_CR36","doi-asserted-by":"publisher","first-page":"251581632211281","DOI":"10.1177\/25158163221128185","volume":"5","author":"O Lekontseva","year":"2022","unstructured":"\u2022 Lekontseva O, Wang M, Amoozegar F. Predictors of clinical response to erenumab in patients with migraine. Cephalalgia Reports. 2022;5:251581632211281. Predictors in migraine.","journal-title":"Cephalalgia Reports"},{"issue":"7","key":"1183_CR37","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","volume":"16","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U. A Scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals (Basel). 2023;16(7):934.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1183_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K, et al. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain. 2023;24(1):23.","journal-title":"J Headache Pain"},{"key":"1183_CR39","doi-asserted-by":"crossref","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A. Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand. 2021;144(3):325\u201333.","DOI":"10.1111\/ane.13472"},{"key":"1183_CR40","doi-asserted-by":"crossref","unstructured":"\u2022 Salem-Abdou H, Simonyan D, Puymirat J. Identification of predictors of response to Erenumab in a cohort of patients with migraine. Cephalalgia Reports. 202;4:25158163211026650. Predictors in migraine.","DOI":"10.1177\/25158163211026646"},{"issue":"10","key":"1183_CR41","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1111\/ene.15458","volume":"29","author":"A Gonzalez-Martinez","year":"2022","unstructured":"\u2022\u2022 Gonzalez-Martinez A, Pag\u00e1n J, Sanz-Garc\u00eda A, Garc\u00eda-Azor\u00edn D, Rodr\u00edguez-Vico JS, Jaimes A, et al. Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: a multicenter Spanish study. Eur J Neurol. 2022;29(10):3102\u201311. Predictors using a machine-learning approach and large sample size.","journal-title":"Eur J Neurol"},{"issue":"9","key":"1183_CR42","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1007\/s10072-022-06190-w","volume":"43","author":"I Cetta","year":"2022","unstructured":"Cetta I, Messina R, Zanandrea L, Colombo B, Filippi M. Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study. Neurol Sci. 2022;43(9):5769\u201371.","journal-title":"Neurol Sci"},{"issue":"1","key":"1183_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-023-01585-2","volume":"24","author":"A Mu\u00f1oz-Vendrell","year":"2023","unstructured":"Mu\u00f1oz-Vendrell A, Campoy S, Caronna E, Alpuente A, Torres-Ferrus M, Nieves Castellanos C, et al. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. J Headache Pain. 2023;24(1):63.","journal-title":"J Headache Pain"},{"key":"1183_CR44","doi-asserted-by":"publisher","first-page":"1220285","DOI":"10.3389\/fneur.2023.1220285","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Suzuki K, Shiina T, Haruyama Y, Hirata K. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol. 2023;14:1220285.","journal-title":"Front Neurol"},{"key":"1183_CR45","doi-asserted-by":"crossref","unstructured":"\u2022 Zecca C, Cargnin S, Schankin C, Giannantoni NM, Viana M, Maraffi I, et\u00a0al. Clinic and genetic predictors in response to erenumab. Eur J Neurol. 2022;29(4):1209\u201317. Predictors in migraine.","DOI":"10.1111\/ene.15236"},{"issue":"2","key":"1183_CR46","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1358\/dnp.2010.23.2.1475909","volume":"23","author":"A Recober","year":"2010","unstructured":"Recober A, Goadsby PJ. Calcitonin gene-related peptide (CGRP): a molecular link between obesity and migraine? Drug News Perspect. 2010;23(2):112\u20137.","journal-title":"Drug News Perspect"},{"key":"1183_CR47","doi-asserted-by":"crossref","unstructured":"Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, et\u00a0al. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor. Eur J Neurol. 2023;30(6):1764\u201373.","DOI":"10.1111\/ene.15761"},{"key":"1183_CR48","doi-asserted-by":"crossref","unstructured":"Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain. 2023;24(1):16.","DOI":"10.1186\/s10194-023-01552-x"},{"issue":"6","key":"1183_CR49","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/rapm-2018-100196","volume":"44","author":"M Barad","year":"2019","unstructured":"Barad M, Sturgeon JA, Fish S, Dexter F, Mackey S, Flood PD. Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain. Reg Anesth Pain Med. 2019;44(6):660\u20138.","journal-title":"Reg Anesth Pain Med"},{"key":"1183_CR50","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, et\u00a0al. Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol. 2021. Predictors in CM.","DOI":"10.1111\/ene.15197"},{"key":"1183_CR51","unstructured":"Gonz\u00e1lez-Mart\u00ednez A, Muro I, Quintas S, Chaparro M, Gisbert JP, Sanz-Garc\u00eda A, et\u00a0al. Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics. Gastroenterol Hepatol. 2023;S0210\u20135705(23)00331-X."},{"key":"1183_CR52","doi-asserted-by":"crossref","unstructured":"Arzani M, Jahromi SR, Ghorbani Z, Vahabizad F, Martelletti P, Ghaemi A, et\u00a0al. Gut-brain axis and migraine headache: a comprehensive review. J Headache Pain. 2020;21(1).","DOI":"10.1186\/s10194-020-1078-9"},{"issue":"1","key":"1183_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-022-01415-x","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, et al. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain. 2022;23(1):56.","journal-title":"J Headache Pain"},{"key":"1183_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.805334","volume":"12","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, G\u00e9rard P. Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol. 2021;12: 805334.","journal-title":"Front Neurol"},{"key":"1183_CR55","doi-asserted-by":"crossref","unstructured":"\u2022 Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6\u2009months. J Headache Pain. 2021;22(1):120. Predictors of MO in CM.","DOI":"10.1186\/s10194-021-01328-1"},{"issue":"8","key":"1183_CR56","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/03331024221076481","volume":"42","author":"S Kwon","year":"2022","unstructured":"Kwon S, Gil YE, Lee MJ. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia. 2022;42(8):705\u201314.","journal-title":"Cephalalgia"},{"issue":"5","key":"1183_CR57","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/ene.15740","volume":"30","author":"AA Argyriou","year":"2023","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al. Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real-world data from a Greek registry. Eur J Neurol. 2023;30(5):1435\u201342.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1183_CR58","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32.","journal-title":"J Headache Pain"},{"issue":"1","key":"1183_CR59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, et al. Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol. 2022;22(1):512.","journal-title":"BMC Neurol"},{"issue":"8","key":"1183_CR60","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/ene.15364","volume":"29","author":"M Khalil","year":"2022","unstructured":"\u2022\u2022 Khalil M, Moreno-Ajona D, Villar-Mart\u00ednez MD, Greenwood F, Hoffmann J, Goadsby PJ. Erenumab in chronic migraine: experience from a UK tertiary centre and comparison with other real-world evidence. Eur J Neurol. 2022;29(8):2473\u201380. Predictors in CM.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1183_CR61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-021-01267-x","volume":"22","author":"R Belv\u00eds","year":"2021","unstructured":"\u2022 Belv\u00eds R, Irimia P, Pozo-Rosich P, Gonz\u00e1lez-Oria C, Cano A, Viguera J, et al. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. J Headache Pain. 2021;22(1):74. Predictors in migraine.","journal-title":"J Headache Pain"},{"key":"1183_CR62","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, et\u00a0al. Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol. 2022;29(4):1198\u2013208. Predictors in CM.","DOI":"10.1111\/ene.15197"},{"key":"1183_CR63","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Fan Cheng, Qinyao Wu, Mariam Hussain, Victoria Wilkinson, Lisa Wilson, Modar Khalil, Fayyaz Ahmed. Efficacy of fremanezumab in resistant and refractory chronic migraine patients: real-world data from the Hull Migraine Clinic, UK. AN. 2022;5(2).. Predictors in CM.","DOI":"10.33140\/AN.05.02.01"},{"key":"1183_CR64","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, et\u00a0al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;21(1):69. Predictors in CM.","DOI":"10.1186\/s10194-020-01143-0"},{"issue":"1","key":"1183_CR65","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-020-01171-w","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Caponnetto V, Gabriele A, Affaitati G, et al. Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain. 2020;21(1):102.","journal-title":"J Headache Pain"},{"key":"1183_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.895476","volume":"13","author":"M Nowaczewska","year":"2022","unstructured":"\u2022 Nowaczewska M, Straburzy\u0144ski M, Waliszewska-Pros\u00f3\u0142 M, Meder G, Janiak-Kiszka J, Ka\u017amierczak W. Cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine\u2014a real-life study. Front Neurol. 2022;13: 895476. Predictors in migraine.","journal-title":"Front Neurol"},{"issue":"1","key":"1183_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F, et al. Association between response to triptans and response to erenumab: real-life data. J Headache Pain. 2021;22(1):1.","journal-title":"J Headache Pain"},{"issue":"2","key":"1183_CR68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.26658","volume":"94","author":"G G\u00e1rate","year":"2023","unstructured":"\u2022\u2022 G\u00e1rate G, Gonz\u00e1lez-Quintanilla V, Gonz\u00e1lez A, Pascual M, P\u00e9rez-Pereda S, Madera J, et al. Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol. 2023;94(2):285\u201394. Predictors in CM.","journal-title":"Ann Neurol"},{"issue":"5","key":"1183_CR69","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ana.26472","volume":"92","author":"A Alpuente","year":"2022","unstructured":"\u2022 Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P. Salivary CGRP and erenumab treatment response: towards precision medicine in migraine. Ann Neurol. 2022;92(5):846\u201359. Predictors in migraine.","journal-title":"Ann Neurol"},{"issue":"1","key":"1183_CR70","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s10194-022-01526-5","volume":"23","author":"TJ Schwedt","year":"2022","unstructured":"\u2022 Schwedt TJ, Nikolova S, Dumkrieger G, Li J, Wu T, Chong CD. Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab. J Headache Pain. 2022;23(1):159. Predictors in migraine.","journal-title":"J Headache Pain"},{"key":"1183_CR71","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77146","volume":"11","author":"H Basedau","year":"2022","unstructured":"\u2022 Basedau H, Sturm LM, Mehnert J, Peng KP, Schellong M, May A. Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study. Elife. 2022;11:e77146. Predictors in migraine.","journal-title":"Elife"},{"issue":"1","key":"1183_CR72","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10194-022-01426-8","volume":"23","author":"H Schenk","year":"2022","unstructured":"Schenk H, Holle D, Nsaka M, Kleinschnitz C, Glas M, Scheffler A. Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study. J Headache Pain. 2022;23(1):55.","journal-title":"J Headache Pain"},{"issue":"6","key":"1183_CR73","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1007\/s10072-022-05870-x","volume":"43","author":"S Guerzoni","year":"2022","unstructured":"\u2022 Guerzoni S, Baraldi C, Pensato U, Favoni V, Lo Castro F, Cainazzo MM, et al. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci. 2022;43(6):3823\u201330. Predictors in CM.","journal-title":"Neurol Sci"},{"key":"1183_CR74","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12883-023-03203-9","volume":"23","author":"K Kaltseis","year":"2023","unstructured":"Kaltseis K, Filippi V, Frank F, Eckhardt C, Schiefecker A, Broessner G. Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an Austrian case series. BMC Neurol. 2023;23:174.","journal-title":"BMC Neurol"},{"issue":"5","key":"1183_CR75","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/ene.15260","volume":"29","author":"LF Iannone","year":"2022","unstructured":"\u2022\u2022 Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. 2022;29(5):1505\u201313. Predictors in CM.","journal-title":"Eur J Neurol"},{"key":"1183_CR76","unstructured":"Pathak P, Yue L, Gupta S, Fang J, Cheadle MA, Tiwari S, et\u00a0al. Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey. Curr Med Res Opin. 2023;1\u20137."},{"issue":"1","key":"1183_CR77","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22(1):154.","journal-title":"J Headache Pain"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01183-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-023-01183-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01183-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T03:05:14Z","timestamp":1735009514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-023-01183-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1183"],"URL":"https:\/\/doi.org\/10.1007\/s11916-023-01183-6","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"16 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ethics approval was not required for this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Carmen S\u00e1nchez-Rodr\u00edguez has no relevant financial or non-financial interests to disclose. Ana Beatriz Gago-Veiga has received honoraria from Lilly, Novartis, TEVA, Abbvie-Allergan, Exeltis, and Chiesi. David Garc\u00eda-Azor\u00edn reports payment or honoraria for lectures from Teva, Lilly, Allergan-Abbvie, Novartis, and Lundbeck and has served on an advisory board for Allergan-Abbvie. \u00c1ngel Luis Guerrero-Peral has received honoraria from Lilly, TEVA, Novartis, Allergan-Abbvie, and Exeltis and research support from Allegan-Abbvie and TEVA. Alicia Gonzalez-Martinez has received speaker honoraria from TEVA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}